Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches (Q35034555)

5 August 2017

title

Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches (English)

1 reference

5 August 2017

1 reference

J Lehmann-Che

1

1 reference

5 August 2017

F Amira-Bouhidel

2

1 reference

5 August 2017

E Turpin

3

1 reference

5 August 2017

M Antoine

4

1 reference

5 August 2017

H Soliman

5

1 reference

5 August 2017

L Legres

6

1 reference

5 August 2017

C Bocquet

7

1 reference

5 August 2017

R Bernoud

8

1 reference

5 August 2017

E Flandre

9

1 reference

5 August 2017

M Varna

10

1 reference

5 August 2017

A de Roquancourt

11

1 reference

5 August 2017

L-F Plassa

12

1 reference

5 August 2017

S Giacchetti

13

1 reference

5 August 2017

M Espié

14

1 reference

5 August 2017

C de Bazelaire

15

1 reference

5 August 2017

L Cahen-Doidy

16

1 reference

5 August 2017

E Bourstyn

17

1 reference

5 August 2017

A Janin

18

1 reference

5 August 2017

H de Thé

19

1 reference

5 August 2017

P Bertheau

20

1 reference

5 August 2017

language of work or name

English

0 references

publication date

3 May 2011

1 reference

British Journal of Cancer

5 August 2017

published in

1 reference

5 August 2017

volume

104

1 reference

5 August 2017

issue

11

1 reference

5 August 2017

page(s)

1739-1746

1 reference

Image-guided breast biopsy: state-of-the-art.

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Current issues in ER and HER2 testing by IHC in breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

HER-2 and topoisomerase II as predictors of response to chemotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Changes in allelic imbalances in locally advanced breast cancers after chemotherapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Gene expression and clonality analysis of the androgen receptor and phosphoglycerate kinase genes in polygonal cells and cuboidal cells in so-called pulmonary sclerosing hemangioma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

HER2 testing: a review of detection methodologies and their clinical performance

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Comparative multi-methodological measurement of ERBB2 status in breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Biology of HER2 and its importance in breast cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Clonal composition of malignant fibrous histiocytoma: analysis by PCR-based assay of the human androgen receptor gene (HUMARA).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Desmoid tumor is a clonal cellular proliferation: PCR amplification of HUMARA for analysis of patterns of X-chromosome inactivation.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Comparison of fluorescent in situ hybridization HER-2/neu results on core needle biopsy and excisional biopsy in primary breast cancer

8 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.135

Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.135

Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.135

Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.135

Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.135

HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.135

Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.135

HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.135

Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.135

Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2011.135

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111154

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

25 October 2018

1 reference

12 December 2020

Gastrointestinal stromal tumor and gastric adenocarcinoma collision tumors

1 reference

12 December 2020

Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies

1 reference

12 December 2020

Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma

1 reference

12 December 2020

Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event

1 reference

12 December 2020

Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome

1 reference

12 December 2020

API2-MALT1 chimeric transcript-positive gastroduodenal MALT lymphoma with subsequent development of adenocarcinoma as a collision tumour over a clinical course of 7 years

1 reference

12 December 2020

Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR

1 reference

12 December 2020

Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2011.135

1 reference

5 August 2017

1 reference

5 August 2017

1 reference